ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GW Pharmaceuticals, in Porton Down, England, has launched Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis, in the U.K. The drug contains two cannabinoid active ingredients—THC (Δ9-tetrahydrocannabinol) and CBD (cannabidiol)—both derived from whole extracts of the Cannabis sativa plant. Bayer Schering Pharma has licensed and will distribute the drug. GW will receive a $15 million milestone payment from Bayer Schering to mark U.K. approval of the drug.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X